- $1.20bn
- $2.53bn
- $1.41bn
- 67
- 27
- 84
- 62
Annual income statement for Ingevity, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1,216 | 1,392 | 1,668 | 1,692 | 1,406 |
| Cost of Revenue | |||||
| Gross Profit | 466 | 513 | 570 | 472 | 455 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 981 | 1,229 | 1,399 | 1,702 | 1,942 |
| Operating Profit | 235 | 163 | 270 | -10.1 | -536 |
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 235 | 163 | 270 | -10.1 | -536 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 181 | 118 | 212 | -5.4 | -430 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 181 | 118 | 212 | -5.4 | -430 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 181 | 118 | 212 | -5.4 | -430 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 4.77 | 4.79 | 5.89 | 3.39 | 0.762 |